Immunome, Inc. (NASDAQ:IMNM – Get Free Report) has earned an average recommendation of “Buy” from the six research firms that are presently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have covered the stock in the last year is $29.80.
A number of analysts recently commented on IMNM shares. Guggenheim started coverage on shares of Immunome in a report on Monday, April 15th. They issued a “buy” rating and a $35.00 target price on the stock. JPMorgan Chase & Co. started coverage on shares of Immunome in a report on Tuesday, April 30th. They issued an “overweight” rating and a $24.00 target price on the stock. Wedbush reiterated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a report on Thursday. Finally, Piper Sandler started coverage on shares of Immunome in a report on Friday, May 31st. They issued an “overweight” rating and a $27.00 target price on the stock.
View Our Latest Analysis on IMNM
Insider Activity
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in IMNM. Cerity Partners LLC purchased a new position in Immunome during the fourth quarter valued at approximately $656,000. Emfo LLC purchased a new position in Immunome during the fourth quarter valued at approximately $633,000. Jump Financial LLC purchased a new position in Immunome during the fourth quarter valued at approximately $172,000. Mayo Clinic purchased a new position in Immunome during the fourth quarter valued at approximately $1,161,000. Finally, Avidity Partners Management LP purchased a new position in Immunome during the fourth quarter valued at approximately $14,268,000. 44.58% of the stock is owned by hedge funds and other institutional investors.
Immunome Trading Up 3.0 %
IMNM stock opened at $16.51 on Wednesday. Immunome has a 52 week low of $6.13 and a 52 week high of $30.96. The company has a market capitalization of $990.10 million, a price-to-earnings ratio of -2.19 and a beta of 1.79. The firm’s 50-day moving average is $13.81 and its two-hundred day moving average is $17.62.
Immunome (NASDAQ:IMNM – Get Free Report) last released its earnings results on Tuesday, May 14th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.46. Immunome had a negative net margin of 1,829.44% and a negative return on equity of 37.33%. The business had revenue of $1.03 million for the quarter, compared to the consensus estimate of $4.00 million. On average, equities research analysts predict that Immunome will post -1.45 earnings per share for the current year.
Immunome Company Profile
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Read More
- Five stocks we like better than Immunome
- Overbought Stocks Explained: Should You Trade Them?
- Is Crypto Cool Again? What Stocks You Should Be Watching
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Why Call Options Volume for These 2 Stocks Spiked Together
- 3 Small Caps With Big Return Potential
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.